Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations
CONCLUSIONS: Given the effectiveness of systemic treatments in hematologic malignancies, the oligometastasis stage is of little importance. A curative intent after local radiation therapy, even advanced stage, is possible, both with residual disease for advanced Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or solitary plasmocytoma, and even without evidence of disease after chemotherapy for Hodgkin or non-Hodgkin lymphoma. The role of new treatments, such as CAR T cells, allows us to consider radiation therapy after systemic treatment of relapsed diseases with low volume recurrence, which can be considered oligorecur...
Source: Cancer Radiotherapie - December 24, 2023 Category: Cancer & Oncology Authors: L Ollivier K Debbi N-H To A Cailleteau S Supiot A Mervoyer V Guimas Y Belkac émi Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment
CONCLUSION: High-dose- or low-dose-/pulsed-dose rate brachytherapy seemed to be as effective and well tolerated in our experience of 61 patients.PMID:38072744 | DOI:10.1016/j.canrad.2023.06.031 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - December 10, 2023 Category: Cancer & Oncology Authors: M Cuenin J Salleron D Peiffert É Meknaci P Gallet Y Abushama J-F Py S Renard Source Type: research
